S
Stephanie Popping
Researcher at Erasmus University Rotterdam
Publications - 19
Citations - 317
Stephanie Popping is an academic researcher from Erasmus University Rotterdam. The author has contributed to research in topics: Medicine & Men who have sex with men. The author has an hindex of 6, co-authored 13 publications receiving 224 citations.
Papers
More filters
Journal ArticleDOI
Declining Hepatitis C Virus (HCV) Incidence in Dutch Human Immunodeficiency Virus-Positive Men Who Have Sex With Men After Unrestricted Access to HCV Therapy
Anne Boerekamps,Guido E.L. van den Berk,F. N. Lauw,Eliane M. S. Leyten,Marjo E. E. van Kasteren,Arne van Eeden,Dirk Posthouwer,Mark A. A. Claassen,Anton S M Dofferhoff,D. W. M. Verhagen,Wouter F W Bierman,Kamilla D. Lettinga,Frank P. Kroon,Corine E Delsing,Paul H. P. Groeneveld,Robert Soetekouw,Edgar J G Peters,Sebastiaan J. Hullegie,Stephanie Popping,David A. M. C. van de Vijver,Charles A. Boucher,Joop E. Arends,Bart J. A. Rijnders +22 more
TL;DR: Unrestricted DAA availability in the Netherlands was followed by a 51% decrease in acute HCV infections among HIV-positive MSM, which contradicts a decrease in risk behavior as an alternative explanation.
Journal ArticleDOI
The global campaign to eliminate HBV and HCV infection: International Viral Hepatitis Elimination Meeting and core indicators for development towards the 2030 elimination goals
Stephanie Popping,Debora Bade,Charles A. Boucher,Mark van der Valk,Manal Elsayed,Olafsson Sigurour,Vana Sypsa,Timothy R. Morgan,Amiran Gamkrelidze,Constance Mukabatsinda,Sylvie Deuffic-Burban,Michael Ninburg,Jordan J. Feld,Margaret Hellard,John W. Ward +14 more
TL;DR: The current status of viral hepatitis elimination programmes across multiple countries, challenges in achieving elimination and the core indicators for monitoring progress are discussed, approaches that have failed and successful elimination plans.
Journal ArticleDOI
Early treatment of acute hepatitis C infection is cost-effective in HIV-infected men-who-have-sex-with-men.
Stephanie Popping,Sebastiaan J. Hullegie,Anne Boerekamps,Bart J. A. Rijnders,Robert J. de Knegt,Jürgen K. Rockstroh,Annelies Verbon,Charles A. Boucher,Brooke E Nichols,Brooke E Nichols,David A. M. C. van de Vijver +10 more
TL;DR: Early DAA treatment for HIV-infected MSM is an excellent and sustainable tool to meet the WHO goal of eliminating HCV in 2030.
Journal ArticleDOI
Treatment of acute hepatitis C genotypes 1 and 4 with 8 weeks of grazoprevir plus elbasvir (DAHHS2): an open-label, multicentre, single-arm, phase 3b trial
Anne Boerekamps,Anja De Weggheleire,Guido E.L. van den Berk,F. N. Lauw,Mark A. A. Claassen,Dirk Posthouwer,Wouter F W Bierman,Sebastiaan J. Hullegie,Stephanie Popping,David A C M van de Vijver,Anthonius S. M. Dofferhoff,Gert Jan Kootstra,Eliane M. S. Leyten,Jan G den Hollander,Marjo E. E. van Kasteren,Robert Soetekouw,Heidi S. M. Ammerlaan,Janke Schinkel,Eric Florence,Joop E. Arends,Bart J. A. Rijnders +20 more
TL;DR: 8 weeks of grazoprevir plus elbasvir was highly effective for the treatment of acute HCV genotype 1 or 4 infection and whether treatment can be shortened during the acute phase of HCV infection is investigated.
Journal ArticleDOI
Emergence and Persistence of Letermovir-Resistant Cytomegalovirus in a Patient With Primary Immunodeficiency.
Stephanie Popping,Virgil A. S. H. Dalm,Nadine Lübke,Veronica Di Cristanziano,Rolf Kaiser,Charles A. Boucher,Jeroen J. A. van Kampen +6 more
TL;DR: This case indicates that the C325Y mutation in UL56 does not significantly alter fitness of cytomegalovirus in vivo and the letermovir-resistant variant was able to reactivate without drug selective pressure.